MannKind Corp (MNKD) stock
MNKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30273% above fair value
$4.13−0.03 (-0.72%)
Close on Nov 13, 2026Market cap $1.33BP/E –Yield –
MannKind ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
MannKind's ebitda for the twelve months ending Sep 30, 2026 was $14.16M, down 82.6% year over year. For fiscal 2025 it was $51.09M, down 36.1% from the year before. The highest annual figure on record is $79.96M in fiscal 2024.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.09M | -36.1% |
| FY2024 | Dec 31, 2024 | $79.96M | +505.1% |
| FY2023 | Dec 31, 2023 | $13.21M | – |
| FY2022 | Dec 31, 2022 | -$60.79M | – |
| FY2021 | Dec 31, 2021 | -$45.04M | – |
| FY2020 | Dec 31, 2020 | -$45.76M | – |
| FY2019 | Dec 31, 2019 | -$43.63M | – |
| FY2018 | Dec 31, 2018 | -$73.74M | – |
| FY2017 | Dec 31, 2017 | -$104.66M | -246.5% |
| FY2016 | Dec 31, 2016 | $71.42M | – |
| FY2015 | Dec 31, 2015 | -$333.66M | – |
| FY2014 | Dec 31, 2014 | -$169.83M | – |
| FY2013 | Dec 31, 2013 | -$157.90M | – |
| FY2012 | Dec 31, 2012 | -$133.96M | – |
| FY2011 | Dec 31, 2011 | -$125.94M | – |
| FY2010 | Dec 31, 2010 | -$136.00M | – |
| FY2009 | Dec 31, 2009 | -$191.05M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $5.05M | -75.9% |
| Q2 FY2026 | Jun 30, 2026 | $6.05M | -18.1% |
| Q1 FY2026 | Mar 31, 2026 | $4.72M | -80.7% |
| Q4 FY2025 | Dec 31, 2025 | -$1.66M | -105.8% |
| Q3 FY2025 | Sep 30, 2025 | $20.96M | +40.8% |
| Q2 FY2025 | Jun 30, 2025 | $7.39M | -59.7% |
| Q1 FY2025 | Mar 31, 2025 | $24.40M | +34.9% |
| Q4 FY2024 | Dec 31, 2024 | $28.66M | +215.5% |
| Q3 FY2024 | Sep 30, 2024 | $14.88M | +142.7% |
| Q2 FY2024 | Jun 30, 2024 | $18.34M | +524.1% |
| Q1 FY2024 | Mar 31, 2024 | $18.08M | – |
| Q4 FY2023 | Dec 31, 2023 | $9.08M | – |
| Q3 FY2023 | Sep 30, 2023 | $6.13M | – |
| Q2 FY2023 | Jun 30, 2023 | $2.94M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.94M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.77M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.63M | – |
| Q2 FY2022 | Jun 30, 2022 | -$19.73M | – |
| Q1 FY2022 | Mar 31, 2022 | -$20.66M | – |
| Q4 FY2021 | Dec 31, 2021 | -$24.98M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.27M | – |
| Q2 FY2021 | Jun 30, 2021 | -$9.26M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.54M | – |
| Q4 FY2020 | Dec 31, 2020 | -$23.24M | – |
| Q3 FY2020 | Sep 30, 2020 | -$8.60M | – |
| Q2 FY2020 | Jun 30, 2020 | -$7.35M | – |
| Q1 FY2020 | Mar 31, 2020 | -$6.58M | – |
| Q4 FY2019 | Dec 31, 2019 | -$10.79M | – |
| Q3 FY2019 | Sep 30, 2019 | -$9.11M | – |
| Q2 FY2019 | Jun 30, 2019 | -$10.58M | – |
| Q1 FY2019 | Mar 31, 2019 | -$13.15M | – |
| Q4 FY2018 | Dec 31, 2018 | -$7.36M | – |
| Q3 FY2018 | Sep 30, 2018 | -$20.51M | – |
| Q2 FY2018 | Jun 30, 2018 | -$19.78M | – |
| Q1 FY2018 | Mar 31, 2018 | -$26.08M | – |
| Q4 FY2017 | Dec 31, 2017 | -$28.02M | – |
| Q3 FY2017 | Sep 30, 2017 | -$27.26M | – |
| Q2 FY2017 | Jun 30, 2017 | -$30.69M | – |
| Q1 FY2017 | Mar 31, 2017 | -$18.69M | – |
| Q4 FY2016 | Dec 31, 2016 | -$10.77M | – |
See a number that looks wrong?